News >

Dacomitinib Approaches EU Approval for EGFR+ NSCLC

Jason M. Broderick @jasoncology
Published: Friday, Feb 01, 2019

Chris Boshoff, MD, PhD

Chris Boshoff, MD, PhD
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of dacomitinib (Vizimpro) for the frontline treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) with EGFR-activating mutations, according to Pfizer, the manufacturer of the pan-human EGFR TKI.

The European Commission will now review the CHMP recommendation and make a final decision on whether to approve dacomitinib for use in the European Union.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x